Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes

Retrieved from https://s3-us-west-1.amazonaws.com/paperchase-aging/pdf/JEdEuyJn5EK48ffWR.pdf, via http://www.aging-us.com/article/JEdEuyJn5EK48ffWR on 1 December 2016 According to http://www.aging-us.com/article/JEdEuyJn5EK48ffWR: received: August 24, 2016 ; accepted: November 16, 2016 ; published: November 30, 2016 Abstract: Numerous studies suggest that rapamycin treatment promotes insulin resistance, implying that rapamycin could have negative effects on patients with, or at risk for, type 2 diabetes (T2D). New evidence, however, indicates that rapamycin treatment produces some benefits to energy metabolism, even in the context of T2D. Here, we survey 5 mouse models of T2D (KK, KK-Ay, NONcNZO10, BKS-db/db, TALLYHO) to quantify effects of rapamycin on well-recognized markers of glucose homeostasis within a wide range of T2D environments. Interestingly, dietary rapamycin treatment did not exacerbate impaired glucose or insulin tolerance, or elevate circulating lipids as T2D progressed. In fact, rapamycin increased insulin sensitivity and reduced weight gain in 3 models, and decreased hyperinsulinemia in 2 models. A key covariate of this genetically-based, differential response was pancreatic insulin content (PIC): Models with low PIC exhibited more beneficial effects than models with high PIC. However, a minimal PIC threshold may exist, below which hypoinsulinemic hyperglycemia develops, as it did in TALLYHO. Our results, along with other studies, indicate that beneficial or detrimental metabolic effects of rapamycin treatment, in a diabetic or pre-diabetic context, are driven by the interaction of rapamycin with the individual model’s pancreatic physiology. Corresponding Author: David E. Harrison David.Harrison@jax.org